The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

Retail chatter around Moleculin Biotech surged on Monday after the company said the European Medicines Agency had approved ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

The European Union's health regulator said on Wednesday it was reviewing French drugmaker Valneva's chikungunya vaccine after ...

The European drugs regulator said on Thursday its safety panel has confirmed suicidal thoughts as a side effect of ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin” or the "Company”), a late-stage pharmaceutical company with a broad ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

Both the FDA and EMA have suspended Ixchiq’s use in older adults after post-marketing serious adverse events that include two ...

The FDA and CDC have also recommended pausing the use of Ixchiq in seniors 60 years and older while safety investigations are ...

New research reveals the potential of drugs that have been on the market for decades to treat diseases other than those for ...

Few areas of healthcare are as sensitive as cancer treatment. Each year, around 44,000 cancer tumours are diagnosed here.